Liao W, Florén C H
Department of Internal Medicine, Lund University, Malmö General Hospital, Sweden.
Hepatology. 1993 May;17(5):898-907.
Tumor necrosis factor mediates most biological activities of endotoxin and also, in part, mediates endotoxin-induced disturbances in lipid metabolism. In this study, the effect of tumor necrosis factor on low-density lipoprotein receptor activity was investigated in cells of HepG2, a well-differentiated human hepatoma cell line. Pretreatment of the cells with tumor necrosis factor leads to enhanced binding, uptake and degradation of 125I-labeled low-density lipoprotein. This effect of tumor necrosis factor was dose and time dependent. Tumor necrosis factor-stimulated enhancement of low-density lipoprotein binding occurred at all stages of cell growth. However, addition of an excess of unlabeled low-density lipoprotein, to down-regulate low-density lipoprotein receptors before exposure to tumor necrosis factor of the cells, completely abolished the effects of tumor necrosis factor. Competition experiments using unlabeled low-density lipoprotein and blockage experiments with a monoclonal low-density lipoprotein receptor antibody showed that tumor necrosis factor-stimulated low-density lipoprotein binding takes place through stimulation of low-density lipoprotein receptors. Comparison of the kinetics of specific low-density lipoprotein binding in the unstimulated cells and in the tumor necrosis factor-stimulated cells indicated that tumor necrosis factor caused a 30% increase in maximum velocity with no significant change in Michaelis constant, suggesting that tumor necrosis factor increases the number of low-density lipoprotein receptors on the cells rather than changing binding affinity. Preincubation of the cells with cycloheximide or actinomycin D totally abolished the up-regulatory effect of tumor necrosis factor on low-density lipoprotein receptors. Tumor necrosis factor did not stimulate proliferation of HepG2 cells, as judged by cell protein determination or by [3H]thymidine incorporation. In conclusion, this study suggests that tumor necrosis factor up-regulates expression of low-density lipoprotein receptors on HepG2 cells by stimulation of de novo synthesis of receptors, independent of cell growth.
肿瘤坏死因子介导内毒素的大多数生物学活性,并且在一定程度上也介导内毒素诱导的脂质代谢紊乱。在本研究中,在人肝癌细胞系HepG2细胞中研究了肿瘤坏死因子对低密度脂蛋白受体活性的影响。用肿瘤坏死因子预处理细胞导致125I标记的低密度脂蛋白的结合、摄取和降解增强。肿瘤坏死因子的这种作用具有剂量和时间依赖性。肿瘤坏死因子刺激的低密度脂蛋白结合增强发生在细胞生长的所有阶段。然而,在细胞暴露于肿瘤坏死因子之前加入过量的未标记低密度脂蛋白以下调低密度脂蛋白受体,完全消除了肿瘤坏死因子的作用。使用未标记低密度脂蛋白的竞争实验和用单克隆低密度脂蛋白受体抗体的阻断实验表明,肿瘤坏死因子刺激的低密度脂蛋白结合是通过刺激低密度脂蛋白受体发生的。比较未刺激细胞和肿瘤坏死因子刺激细胞中特异性低密度脂蛋白结合的动力学表明,肿瘤坏死因子使最大速度增加30%,而米氏常数无显著变化,这表明肿瘤坏死因子增加了细胞上低密度脂蛋白受体的数量而不是改变结合亲和力。用环己酰亚胺或放线菌素D预孵育细胞完全消除了肿瘤坏死因子对低密度脂蛋白受体的上调作用。通过细胞蛋白质测定或[3H]胸腺嘧啶掺入判断,肿瘤坏死因子未刺激HepG2细胞增殖。总之,本研究表明肿瘤坏死因子通过刺激受体的从头合成上调HepG2细胞上低密度脂蛋白受体的表达,与细胞生长无关。